(28 days)
Not Found
No
The device description and performance studies focus on the physical and biological properties of the wound dressing, with no mention of AI or ML technologies.
Yes
The device is intended for the management of exuding wounds, partial and full thickness wounds, which are conditions that require therapeutic intervention. Its function as an effective barrier to reduce microbial penetration and its ability to absorb wound exudate and form a gel directly relate to the treatment and healing of these wounds.
No
Explanation: The device is described as a wound dressing intended to absorb exudate and act as a microbial barrier. Its function is to manage wounds by covering and protecting them, not to diagnose a medical condition.
No
The device description clearly states it is a "soft non-woven fiber based wound care device" made of "synthetic polymers" with a "hydrophilic gelling fiber core" and "backing film." This describes a physical, material-based product, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the management of exuding wounds and as a microbial barrier. This is a therapeutic and protective function applied directly to the wound.
- Device Description: The description details a wound dressing that absorbs exudate and acts as a physical barrier. It does not mention any analysis of biological samples (blood, urine, tissue, etc.) to provide diagnostic information.
- Performance Studies: The performance studies focus on the physical and biological properties of the dressing itself (absorbency, microbial barrier, biocompatibility) and not on the accuracy of a diagnostic test.
IVD devices are used to examine specimens derived from the human body to provide information for the diagnosis, prevention, monitoring, treatment, or alleviation of disease. This wound dressing does not perform such a function.
N/A
Intended Use / Indications for Use
Enluxtra Humifiber™ Wound Dressings are intended as an effective barrier to reduce microbial penetration through the dressing. The Enluxtra Humifiber™ Wound Dressings are for use under healthcare professional's orders for the management of exuding wounds, partial and full thickness wounds, such as pressure ulcers (Stages II-IV), lower extremity ulcers (venous or arterial), diabetic foot ulcers, surgical or traumatic wounds.
Product codes
FRO
Device Description
Enluxtra™ Humifiber™ Wound Dressings are soft non-woven fiber based wound care devices that are designed for use on exuding wounds and as effective barriers to reduce microbial penetration through the dressing.
Enluxtra™ Humifiber™ Wound Dressings are made of synthetic polymers, consisting of a hydrophilic gelling fiber core enclosed between a wound contact fiber layer and backing film. When the dressing is in contact with breached skin/wound and absorbs wound exudate, the polymer fibers form a gel. The backing film supports the gel and allows for simple one-piece removal of the dressing from the wound.
The film prevents fluid strike-through and serves as a microbial barrier to reduce microbial penetration through the dressing.
The Enluxtra™ Humifiber™ Wound Dressings are provided as sterile, single use, disposable devices and will be available in a variety of sizes.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
All necessary verification and validation tests have been performed for the Enluxtra™ Humifiber™ Wound Dressings to assure substantial equivalence to the predicate devices:
ı Absorbency,
- Microbial barrier/strike through,
- Biocompatibility, including the following tests:
1 Cytotoxiciity - ISO Agar Diffusion Non-Toxic/ Passed
2 Intracutaneous (Intradermal) Reactivity Non-irritant/ Passed
3 Maximization Test for Delayed-Type Hypersensitivity Negative for evidence of sensitization
4 Acute Systemic Toxicity Non-Toxic/ Passed
5 Hemolysis Test – Extraction and Direct contact Methods Non-Hemolytic
Bacterial Mutagenicity (not mutagenic)
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
PolyFIT+ Absorbing Dressings (K092351), SoloSite Conformable Dressing (K981150)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
N/A
0
se 1 of 3 510(k) Summary of Safety and Effectiveness Section 5
5. 510(k) Summary
AUG 2 8 2012
This 510(k) summary is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
| APPLICANT: | BASF VENTURE CAPITAL AMERICA INC. | |
|---|---|---|
| PHONE: | (914) 785-4362 | |
| FACSIMILE: | (914) 785-2166 | |
| CONTACT PERSON: | Nadi Ergenc, Ph.D. | |
| DATE PREPARED: | July 30, 2012 | |
| TRADE NAME: | Enluxtra™ Humifiber™ Wound Dressing | |
| COMMON NAME: | Wound Dressing | |
| CLASSIFICATION NAME: | Dressing, Wound, Drug | |
| DEVICE | ||
| CLASSIFICATION: | Unclassified (Pre-Amendment) | |
| PRODUCT CODE | FRO | |
| PREDICATE DEVICES: | Enluxtra™ Humifiber ™ Wound Dressing, Class 1, 510k Exempt, Product Code NAC | |
| PolyFIT+ Absorbing Dressings (K092351), Unclassified | ||
| SoloSite Conformable Dressing (K981150), Unclassified |
Substantially Equivalent To:
The Enluxtra™ Humifiber™ Wound Dressings are substantially equivalent in intended use, principles of operation and technological characteristics to the legally marketed Enluxtra™ Humifiber ™ Wound Dressing, Class 1, 510k Exempt , Product Code NAC, and PolyFIT+ Absorbing Dressings (K092351), Unclassified (Pre-Amendment), Product Code FRO, and SoloSite Conformable Dressing (K981150), Unclassified, Product Code MGQ.
Description of the Device Subject to Premarket Notification:
Enluxtra™ Humifiber™ Wound Dressings are soft non-woven fiber based wound care devices that are designed for use on exuding wounds and as effective barriers to reduce microbial penetration through the dressing.
Enluxtra™ Humifiber™ Wound Dressings are made of synthetic polymers, consisting of a hydrophilic gelling fiber core enclosed between a wound contact fiber layer and backing film. When the dressing is in contact with breached skin/wound and absorbs wound exudate, the polymer fibers form a gel. The backing film supports the gel and allows for simple one-piece removal of the dressing from the wound.
1
510(k) Summary of Safety and Effectiveness Section 5
The film prevents fluid strike-through and serves as a microbial barrier to reduce microbial penetration through the dressing.
The Enluxtra™ Humifiber™ Wound Dressings are provided as sterile, single use, disposable devices and will be available in a variety of sizes.
Indication for Use:
Enluxtra Humifiber™ Wound Dressings are intended as an effective barrier to reduce microbial penetration through the dressing. The Enluxtra Humifiber™ Wound Dressings are for use under healthcare professional's orders for the management of exuding wounds, partial and full thickness wounds, such as pressure ulcers (Stages II-IV), lower extremity ulcers (venous or arterial), diabetic foot ulcers, surgical or traumatic wounds.
Technical Characteristics:
The Enluxtra™ Humifiber™ Wound Dressings have similar physical and technical characteristics to the predicate devices. The Enluxtra™ Humifiber™ Wound Dressings and the predicates have the same design, are made of the same or similar non-resorbable synthetic polymers, are for single use and are sterilized by radiation.
Performance Data:
All necessary verification and validation tests have been performed for the Enluxtra™ Humifiber™ Wound Dressings to assure substantial equivalence to the predicate devices:
ı Absorbency,
- Microbial barrier/strike through,
- Biocompatibility, including the following tests:
| # | Test | Results |
|---|---|---|
| 1 | Cytotoxiciity - ISO Agar Diffusion | Non-Toxic/ Passed |
| 2 | Intracutaneous (Intradermal) Reactivity | Non-irritant/ Passed |
| 3 | Maximization Test for Delayed-Type | |
| Hypersensitivity | Negative for evidence | |
| of sensitization | ||
| 4 | Acute Systemic Toxicity | Non-Toxic/ Passed |
| 5 | Hemolysis Test – | |
| Extraction and Direct contact Methods | Non-Hemolytic |
Bacterial Mutagenicity (not mutagenic)
Premarket Notification
2
510(k) Summary of Safety and Effectivenes Section 5
Basis for Determination of Substantial Equivalence:
Upon reviewing the safety and efficacy information provided in this submission and comparing intended use, principle of operation and overall technological characteristics, the Enluxtra™ Humifiber™ Wound Dressings are determined to be substantially equivalent to existing legally marketed devices.
All performance characteristics of the Enluxtra™ Humifiber™ Wound Dressings are the same or similar as the predicates.
The Enluxtra™ Humifiber™ Wound Dressings raised no new safety concerns relative to biocompatibility. Testing performed on the Enluxtra™ Humifiber™ Wound Dressing showed that it was non-toxic, non-irritant, negative for evidence of sensitization, nonhemolytic and non-mutagenic.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle or other bird-like figure with outstretched wings.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
AUG 28 2012
BASF Venture Capital America, Incorporated % Nadi Ergenc, Ph.D. 100 Campus Drive Floram Park, New Jersey 07932
Re: K12297
Trade/Device Name: Enluxtra™ Humifiber™ Wound Dressings Regulatory Class: Unclassified Product Code: FRO Dated: July 31, 2012 Received: July 31, 2012
Dear Dr. Ergenc:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act
4
Page 2 - Nadi Ergenc, Ph.D.
or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
- Indications for Use Statement
INDICATIONS FOR USE STATEMENT
510(k) Number (if known): K122297
Device Name: Enluxtra Humifiber™ Wound Dressings
Indications for Use:
Enluxtra Humifiber™ Wound Dressings are intended as an effective barrier to reduce microbial penetration through the dressing. The Enluxtra Humifiber™ Wound Dressings are for use under healthcare professional's orders for the management of exuding wounds, partial and full thickness wounds, such as pressure ulcers (Stages II-IV), lower extremity ulcers (venous or arterial), diabetic foot ulcers, surgical or traumatic wounds.
OR
Prescription Use _X (Per 21 CFR 801.109) Over-The-Counter Use
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Daniel Kurefarlim
(Division Sign-Off)
Division of Surgical, Orthopedic, and Restorative Devices
Page 1 of 1
510(k) Number K122297
Page 1 of 1